Free Trial

Biohaven (BHVN) Stock Price, News & Analysis

Biohaven logo
$29.24 +1.02 (+3.62%)
Closing price 03/14/2025 03:58 PM Eastern
Extended Trading
$29.16 -0.08 (-0.26%)
As of 03/14/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Biohaven Stock (NYSE:BHVN)

Key Stats

Today's Range
$28.50
$29.65
50-Day Range
$27.47
$42.67
52-Week Range
$26.80
$60.46
Volume
653,834 shs
Average Volume
1.08 million shs
Market Capitalization
$2.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.15
Consensus Rating
Buy

Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Remove Ads

Biohaven Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

BHVN MarketRank™: 

Biohaven scored higher than 73% of companies evaluated by MarketBeat, and ranked 288th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biohaven has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biohaven's stock forecast and price target.
  • Earnings Growth

    Earnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biohaven is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biohaven is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biohaven has a P/B Ratio of 5.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biohaven's valuation and earnings.
  • Percentage of Shares Shorted

    9.75% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 3.94%, indicating that investor sentiment is improving.
  • Dividend Yield

    Biohaven does not currently pay a dividend.

  • Dividend Growth

    Biohaven does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.75% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 3.94%, indicating that investor sentiment is improving.
  • News Sentiment

    Biohaven has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Biohaven this week, compared to 6 articles on an average week.
  • Search Interest

    Only 6 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,038,629.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biohaven's insider trading history.
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
Cantor Fitzgerald Reduces Earnings Estimates for Biohaven
See More Headlines

BHVN Stock Analysis - Frequently Asked Questions

Biohaven's stock was trading at $37.35 on January 1st, 2025. Since then, BHVN shares have decreased by 21.7% and is now trading at $29.2410.
View the best growth stocks for 2025 here
.

Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings data on Monday, March, 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by $0.29.

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Top institutional shareholders of Biohaven include Vanguard Group Inc. (8.32%), Janus Henderson Group PLC (6.91%), Stifel Financial Corp (6.49%) and Suvretta Capital Management LLC (5.56%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten, George C Clark and Irina Antonijevic.
View institutional ownership trends
.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
3/03/2025
Today
3/14/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:BHVN
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
239
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.15
High Stock Price Target
$76.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+116.0%
Consensus Rating
Buy
Rating Score (0-4)
3.07
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-408,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.34 per share
Price / Book
5.48

Miscellaneous

Free Float
84,942,000
Market Cap
$2.98 billion
Optionable
Optionable
Beta
1.27
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSE:BHVN) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners